Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International Congress
26 Setembro 2024 - 9:00AM
Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage
biopharmaceutical company translating genetic insights into the
development of therapies for central nervous system (CNS) disorders
characterized by neuronal excitation-inhibition imbalance, today
announced the presentation of a poster and platform talk showcasing
its Phase 3 clinical program evaluating ulixacaltamide for adults
with essential tremor (ET) at the Movement Disorders Society (MDS)
2024 International Congress taking place in Philadelphia,
Pennsylvania, September 27 – October 1, 2024.
Praxis at MDS 2024 | Pennsylvania Convention
Center
Meet us at booth #1008 or head to one of our presentations
listed below where we will share progress on our journey to develop
a new ET therapy
Essential3: An Innovative Multi-Study Phase 3 Program to
Evaluate the Efficacy and Safety of Ulixacaltamide
Platform Presentation
- Saturday, September
281:30 – 2:30 PM ET | Group 1: Clinical Trials | Meeting
Room 204C
Poster Presentation
- Sunday, September 291:00 – 3:00 PM ET | Poster
#641 | Exhibit Hall A
Materials will be made available on the Resources page of the
Praxis website following presentation at MDS 2024:
https://praxismedicines.com/resources/.
About UlixacaltamideUlixacaltamide is a
differentiated and highly selective small molecule inhibitor of
T-type calcium channels designed to block abnormal neuronal burst
firing in the Cerebello-Thalamo-Cortical (CTC) circuit correlated
with tremor activity. Ulixacaltamide, the most advanced program
within Praxis’ Cerebrum™ small molecule platform, is currently in
development for the treatment of essential
tremor. www.praxisessentialtremor.com.
About Praxis Praxis Precision Medicines is
a clinical-stage biopharmaceutical company translating insights
from genetic epilepsies into the development of therapies for CNS
disorders characterized by neuronal excitation-inhibition
imbalance. Praxis is applying genetic insights to the discovery and
development of therapies for rare and more prevalent neurological
disorders through our proprietary small molecule platform,
Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™,
using our understanding of shared biological targets and circuits
in the brain. Praxis has established a diversified, multimodal CNS
portfolio including multiple programs across movement disorders and
epilepsy, with four clinical-stage product candidates. For more
information, please visit www.praxismedicines.com and follow us
on Facebook, LinkedIn, Instagram and Twitter/X.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995 and other federal
securities laws, including express or implied statements regarding
Praxis’ future expectations, plans and prospects, including,
without limitation, statements regarding the anticipated timing of
Praxis’ clinical trials, the development of Praxis’ product
candidates and the potential therapeutic effects of Praxis’ product
candidates, as well as other statements containing the words
“anticipate,” “believe,” “continue,” “could,” “endeavor,”
“estimate,” “expect,” “anticipate,” “intend,” “may,” “might,”
“plan,” “potential,” “predict,” “project,” “seek,” “should,”
“target,” “will” or “would” and similar expressions that constitute
forward-looking statements under the Private Securities Litigation
Reform Act of 1995.
The express or implied forward-looking statements included in
this press release are only predictions and are subject to a number
of risks, uncertainties and assumptions, including, without
limitation: uncertainties inherent in clinical trials; the expected
timing of clinical trials, data readouts and the results thereof,
and submissions for regulatory approval or review by governmental
authorities; regulatory approvals to conduct trials; and other
risks concerning Praxis’ programs and operations as described in
its Annual Report on Form 10-K for the year ended December 31, 2023
and other filings made with the Securities and Exchange Commission.
Although Praxis’ forward-looking statements reflect the good faith
judgment of its management, these statements are based only on
information and factors currently known by Praxis. As a result, you
are cautioned not to rely on these forward-looking statements. Any
forward-looking statement made in this press release speaks only as
of the date on which it is made. Praxis undertakes no obligation to
publicly update or revise any forward-looking statement, whether as
a result of new information, future developments or otherwise.
Investor Contact:
Praxis Precision Medicines
investors@praxismedicines.com
857-702-9452
Praxis Precision Medicines (NASDAQ:PRAX)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Praxis Precision Medicines (NASDAQ:PRAX)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024